← Back to headlines
EyePoint Pharmaceuticals Shares Fall After Clinical Trial Setback and Analyst Downgrade
TD Cowen downgrades the biotech firm's stock following disappointing results in a late-stage clinical trial, triggering a broader market sell-off.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
